DASATINIB SANDOZ dasatinib 20 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

dasatinib sandoz dasatinib 20 mg film-coated tablet bottle

accelagen pty ltd - dasatinib, quantity: 20 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; triethyl citrate; hyprolose - dasatinib sandoz is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sandoz is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy

DASATINIB SANDOZ dasatinib 70 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

dasatinib sandoz dasatinib 70 mg film-coated tablet bottle

accelagen pty ltd - dasatinib, quantity: 70 mg - tablet, film coated - excipient ingredients: hyprolose; triethyl citrate; magnesium stearate; hypromellose; croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; titanium dioxide - dasatinib sandoz is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sandoz is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy

DASATINIB SANDOZ dasatinib 50 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

dasatinib sandoz dasatinib 50 mg film-coated tablet bottle

accelagen pty ltd - dasatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: hypromellose; triethyl citrate; magnesium stearate; microcrystalline cellulose; hyprolose; lactose monohydrate; titanium dioxide; croscarmellose sodium - dasatinib sandoz is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sandoz is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy

DASATINIB TARO 100 MG Israel - English - Ministry of Health

dasatinib taro 100 mg

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 100 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

DASATINIB TARO 140 MG Israel - English - Ministry of Health

dasatinib taro 140 mg

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 140 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

DASATINIB TARO 20 MG Israel - English - Ministry of Health

dasatinib taro 20 mg

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 20 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

DASATINIB TARO 50 MG Israel - English - Ministry of Health

dasatinib taro 50 mg

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 50 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

DASATINIB TARO 70 MG Israel - English - Ministry of Health

dasatinib taro 70 mg

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 70 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

DASATINIB TARO 80 MG Israel - English - Ministry of Health

dasatinib taro 80 mg

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 80 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with:* newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Dasatinib Sandoz 100 mg film-coat. tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dasatinib sandoz 100 mg film-coat. tabl.

sandoz sa-nv - dasatinib 100 mg - film-coated tablet - dasatinib